A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)

Trial Profile

A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs LMP1-LMP2-specific T lymphocyte therapy (Primary) ; Rituximab (Primary)
  • Indications Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Mar 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
    • 08 Mar 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top